Form 4: Amicus Therapeutics Acquired by BioMarin

Director Craig A. Wheeler reports the disposal of all equity holdings following the acquisition of Amicus Therapeutics by BioMarin Pharmaceutical Inc.

Summary

• Director Craig A. Wheeler disposed of 84,631 shares of common stock at a price of $14.50 per share.
• Multiple tranches of stock options totaling 313,630 shares were cancelled and converted into cash payments based on the $14.50 merger consideration.
• The transactions were executed in connection with the completed acquisition of Amicus Therapeutics (FOLD) by BioMarin Pharmaceutical Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing documenting the final exit of a director following a completed corporate acquisition.

Positives

• The acquisition price of $14.50 per share provided liquidity for the director's equity holdings.
• All outstanding stock options held by the director were fully vested and converted into cash upon the merger's consummation.

Negatives

• The director no longer holds any direct beneficial ownership in Amicus Therapeutics following the acquisition.

Risks

• No ongoing risks as the company has been acquired and the reporting person has exited their position.

Future Outlook

Not applicable as the company has been acquired.

Industry Context

StockSavvy.ai notes that this filing confirms the finalization of the acquisition of Amicus Therapeutics by BioMarin, reflecting ongoing consolidation trends within the rare disease and biotechnology sectors.

Comparison to Industry Standards

• The cash-out of equity and options at a fixed merger price is standard practice in pharmaceutical M&A transactions.
• The $14.50 valuation aligns with the terms of the definitive merger agreement previously disclosed by the companies.

Stakeholder Impact

• Shareholders have received the merger consideration of $14.50 per share.

Next Steps

• None; the reporting person has zeroed out their holdings.

Key Dates

Keywords

Amicus Therapeutics, BioMarin, Merger, Acquisition, FOLD, Form 4, Insider Transaction